About Biostage (OTCMKTS:BSTG)
Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient's own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.
Industry, Sector and Symbol:
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: N/A
- Sector: Medical
- Symbol: OTCMKTS:BSTG
- Previous Symbol: NASDAQ:BSTG
- CUSIP: N/A
- Web: www.biostage.com
- Current Ratio: 1.10%
- Quick Ratio: 1.09%
Sales & Book Value:
- Annual Sales: $80,000.00
- Price / Sales: 34.25
- Book Value: $0.10 per share
- Price / Book: 0.70
- Trailing EPS: ($0.61)
- Net Income: ($11,570,000.00)
- Return on Equity: -1,031.15%
- Return on Assets: -229.23%
- Employees: 28
- Outstanding Shares: 39,030,000
Frequently Asked Questions for Biostage (OTCMKTS:BSTG)
What is Biostage's stock symbol?
Biostage trades on the OTCMKTS under the ticker symbol "BSTG."
How were Biostage's earnings last quarter?
Biostage, Inc. (OTCMKTS:BSTG) announced its earnings results on Thursday, May, 11th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.09. View Biostage's Earnings History.
Who are some of Biostage's key competitors?
Who are Biostage's key executives?
Biostage's management team includes the folowing people:
- John F. Kennedy, Chairman of the Board
- James J. McGorry, Chief Executive Officer, Director
- Thomas McNaughton Jr., Chief Financial Officer
- Harout DerSimonian, Chief Scientific Officer
- David M. Green, Director
- Blaine H Mckee Ph.D., Director
- John J. Canepa, Independent Director
- Thomas H. Robinson, Independent Director
How do I buy Biostage stock?
Shares of Biostage can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biostage's stock price today?
One share of Biostage stock can currently be purchased for approximately $0.07.
How big of a company is Biostage?
Biostage has a market capitalization of $2.69 million and generates $80,000.00 in revenue each year. The biotechnology company earns ($11,570,000.00) in net income (profit) each year or ($0.61) on an earnings per share basis. Biostage employs 28 workers across the globe.
How can I contact Biostage?
Biostage's mailing address is 84 October Hill Rd Ste 11, HOLLISTON, MA 01746-1371, United States. The biotechnology company can be reached via phone at +1-774-2337300 or via email at [email protected]
MarketBeat Community Rating for Biostage (OTCMKTS BSTG)MarketBeat's community ratings are surveys of what our community members think about Biostage and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Biostage (OTCMKTS:BSTG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 0 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.00)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Biostage (OTCMKTS:BSTG)
Analysts' Ratings History for Biostage (OTCMKTS:BSTG)
(Data available from 11/18/2015 forward)
|8/14/2017||Maxim Group||Reiterated Rating||Hold|
Earnings History and Estimates Chart for Biostage (OTCMKTS:BSTG)
Earnings History by Quarter for Biostage (OTCMKTS BSTG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/9/2017||Q4 2016||($0.21)||($0.20)||$0.03 million||View||Listen|
|8/11/2016||Q216||($0.21)||($0.17)||$48.00 million||$0.03 million||View||Listen|
|3/17/2016||Q415||($0.17)||$1.60 million||$0.01 million||View||Listen|
|8/13/2015||Q215||($0.44)||$23.00 million||$73.00 million||View||N/A|
|3/19/2015||Q4 2014||($0.27)||($0.36)||$0.05 million||View||N/A|
|5/8/2014||Q114||($0.33)||($0.39)||$0.10 million||$0.02 million||View||N/A|
Earnings Estimates for Biostage (OTCMKTS:BSTG)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Biostage (OTCMKTS:BSTG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biostage (OTCMKTS BSTG)
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 7.15%
Insider Trades by Quarter for Biostage (OTCMKTS BSTG)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/24/2017||Saverio Lafrancesca||Insider||Buy||100,000||$0.37||$37,000.00|| |
|8/23/2017||Saverio Lafrancesca||Insider||Buy||150,000||$0.32||$48,000.00|| |
|10/12/2016||Harout Dersimonian||Insider||Buy||10,000||$0.91||$9,100.00|| |
|8/26/2016||John F Kennedy||Director||Buy||16,182||$0.93||$15,049.26|| |
|8/25/2016||James Joseph Mcgorry||Insider||Buy||25,000||$0.96||$24,000.00|| |
|6/21/2016||James Joseph Mcgorry||CEO||Buy||20,000||$1.07||$21,400.00|| |
|6/13/2016||Thomas H Robinson||Director||Buy||32,000||$1.17||$37,440.00|| |
|5/25/2016||John J Canepa||Director||Buy||17,241||$1.46||$25,171.86|| |
|5/20/2016||James Joseph Mcgorry||CEO||Buy||10,000||$1.56||$15,600.00|| |
|5/20/2016||John F Kennedy||Director||Buy||6,500||$1.56||$10,140.00|| |
|5/20/2016||Thomas Mcnaughton||CFO||Buy||5,000||$1.56||$7,800.00|| |
|5/19/2016||Thomas H Robinson||Director||Buy||18,000||$1.36||$24,480.00|| |
|12/17/2015||Saverio Lafrancesca||insider||Sell||2,393||$1.93||$4,618.49|| |
|12/1/2015||John F Kennedy||Director||Buy||9,000||$2.95||$26,550.00|| |
|12/1/2015||Saverio Lafrancesca||Insider||Buy||10,000||$3.01||$30,100.00|| |
|11/19/2015||James Joseph Mcgorry||CEO||Buy||10,000||$1.79||$17,900.00|| |
|11/18/2015||Thomas Mcnaughton||CFO||Buy||10,000||$1.56||$15,600.00|| |
|11/17/2015||David Green||Director||Buy||25,000||$1.34||$33,500.00|| |
|11/17/2015||Thomas Mcnaughton||CFO||Buy||15,000||$1.32||$19,800.00|| |
|9/18/2015||Saverio Lafrancesca||insider||Buy||9,500||$1.29||$12,255.00|| |
|8/28/2015||Saverio Lafrancesca||Insider||Buy||2,500||$0.96||$2,400.00|| |
|8/26/2015||Thomas Mcnaughton||CFO||Buy||10,000||$0.88||$8,800.00|| |
|8/24/2015||John F Kennedy||Director||Buy||12,000||$0.83||$9,960.00|| |
|8/21/2015||James Joseph Mcgorry||CEO||Buy||31,300||$0.74||$23,162.00|| |
|8/21/2015||Thomas Mcnaughton||CFO||Buy||100,000||$0.66||$66,000.00|| |
|6/4/2015||John F Kennedy||Director||Buy||1,000||$2.13||$2,130.00|| |
|6/3/2015||John F Kennedy||Director||Buy||1,000||$1.95||$1,950.00|| |
|6/3/2015||Thomas Mcnaughton||CEO||Buy||16,000||$1.85||$29,600.00|| |
|6/2/2015||David Green||Director||Buy||26,600||$1.81||$48,146.00|| |
|6/2/2015||Thomas Mcnaughton||CEO||Buy||8,000||$1.80||$14,400.00|| |
|6/1/2015||John F Kennedy||Director||Buy||10,000||$1.67||$16,700.00|| |
|6/1/2015||Thomas Mcnaughton||CEO||Buy||3,000||$1.74||$5,220.00|| |
|5/29/2015||Thomas Mcnaughton||CEO||Buy||5,000||$1.91||$9,550.00|| |
|2/18/2015||David Green||CEO||Buy||50,000||$1.75||$87,500.00|| |
|2/13/2015||Thomas Mcnaughton||CFO||Buy||14,000||$2.67||$37,380.00|| |
Headline Trends for Biostage (OTCMKTS:BSTG)
Latest Headlines for Biostage (OTCMKTS BSTG)
No headlines for this company have been tracked by MarketBeat.com
Biostage (OTCMKTS BSTG) Chart for Saturday, November, 18, 2017